Psyence Biomedical (PBM) Competitors $3.64 +0.40 (+12.35%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.60 -0.04 (-1.24%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. ABP, CING, ALVR, LIXT, LSTA, IXHL, LSB, LEXX, CYCC, and SYBXShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Abpro (ABP), Cingulate (CING), AlloVir (ALVR), Lixte Biotechnology (LIXT), Lisata Therapeutics (LSTA), Incannex Healthcare (IXHL), LakeShore Biopharma (LSB), Lexaria Bioscience (LEXX), Cyclacel Pharmaceuticals (CYCC), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors Abpro Cingulate AlloVir Lixte Biotechnology Lisata Therapeutics Incannex Healthcare LakeShore Biopharma Lexaria Bioscience Cyclacel Pharmaceuticals Synlogic Abpro (NASDAQ:ABP) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Does the media favor ABP or PBM? In the previous week, Abpro and Abpro both had 1 articles in the media. Abpro's average media sentiment score of 1.91 beat Psyence Biomedical's score of 1.54 indicating that Abpro is being referred to more favorably in the media. Company Overall Sentiment Abpro Very Positive Psyence Biomedical Very Positive Which has higher earnings & valuation, ABP or PBM? Psyence Biomedical has lower revenue, but higher earnings than Abpro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$180K79.32-$7.23MN/AN/APsyence BiomedicalN/AN/A$1.01MN/AN/A Do analysts prefer ABP or PBM? Abpro currently has a consensus target price of $4.00, indicating a potential upside of 2,145.93%. Given Abpro's stronger consensus rating and higher probable upside, equities analysts plainly believe Abpro is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in ABP or PBM? 23.3% of Abpro shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 20.8% of Abpro shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ABP or PBM more profitable? Company Net Margins Return on Equity Return on Assets AbproN/A N/A -241.16% Psyence Biomedical N/A N/A N/A Which has more volatility & risk, ABP or PBM? Abpro has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. SummaryAbpro beats Psyence Biomedical on 6 of the 10 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.05M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.1774.5225.93Price / SalesN/A437.97517.44183.79Price / Cash1.8146.6837.5660.44Price / Book0.319.6112.166.29Net Income$1.01M-$53.29M$3.28B$270.77M7 Day Performance35.32%0.28%0.87%3.88%1 Month Performance13.04%5.73%4.96%4.88%1 Year Performance-96.10%10.52%60.75%26.01% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence Biomedical0.6605 of 5 stars$3.64+12.3%N/A-96.3%$6.05MN/A0.00N/APositive NewsABPAbpro3.9542 of 5 stars$0.25+0.9%$4.00+1,472.3%N/A$20.39M$183K0.0015Positive NewsCINGCingulate2.5941 of 5 stars$3.76+0.7%$26.25+598.9%-33.5%$20.32MN/A-0.9220ALVRAlloVirN/A$4.00-2.0%N/A-75.2%$20.17MN/A-0.20110High Trading VolumeLIXTLixte Biotechnology0.8793 of 5 stars$4.23+2.2%N/A+203.5%$19.29MN/A-3.284Short Interest ↓Gap DownLSTALisata Therapeutics3.2398 of 5 stars$2.17-1.9%$23.50+983.4%-27.2%$19.01M$1M-0.9730Short Interest ↓Gap DownIXHLIncannex Healthcare0.1613 of 5 stars$0.62-2.2%N/A-65.1%$18.31M$10K-0.513News CoverageShort Interest ↑Gap UpLSBLakeShore Biopharma1.2755 of 5 stars$0.84+1.6%N/A-84.1%$17.34M$85.67M0.00773News CoverageShort Interest ↓Gap DownLEXXLexaria Bioscience3.8814 of 5 stars$0.88-0.6%$4.00+354.0%-66.2%$17.23M$460K-1.317Positive NewsShort Interest ↓CYCCCyclacel Pharmaceuticals0.423 of 5 stars$7.65-0.5%N/A-97.5%$17.14M$40K-0.0114Short Interest ↑SYBXSynlogic1.6544 of 5 stars$1.46flatN/A+12.4%$17.08M$10K-18.2580Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Abpro Alternatives Cingulate Alternatives AlloVir Alternatives Lixte Biotechnology Alternatives Lisata Therapeutics Alternatives Incannex Healthcare Alternatives LakeShore Biopharma Alternatives Lexaria Bioscience Alternatives Cyclacel Pharmaceuticals Alternatives Synlogic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBM Stock Alerts